Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1971 3
1973 1
1976 1
1979 1
1980 1
1981 3
1983 1
1984 4
1985 1
1986 1
1987 3
1988 3
1989 8
1990 2
1991 6
1992 5
1993 3
1994 2
1995 2
1996 4
1997 5
1998 7
1999 5
2000 5
2001 2
2002 6
2003 7
2004 11
2005 16
2006 13
2007 16
2008 12
2009 14
2010 15
2011 15
2012 16
2013 33
2014 31
2015 17
2016 22
2017 31
2018 33
2019 44
2020 50
2021 74
2022 85
2023 75
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

668 results

Results by year

Filters applied: . Clear all
Page 1
The Reply.
Alabdaljabar MS, Vincent ML, Thoendel MJ, Issa M. Alabdaljabar MS, et al. Among authors: issa m. Am J Med. 2023 Sep;136(9):e183. doi: 10.1016/j.amjmed.2023.04.028. Am J Med. 2023. PMID: 37612023 No abstract available.
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Taylor PC, et al. Among authors: issa m. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. Ann Rheum Dis. 2022. PMID: 34706874 Free PMC article.
Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders.
Novarino G, Fenstermaker AG, Zaki MS, Hofree M, Silhavy JL, Heiberg AD, Abdellateef M, Rosti B, Scott E, Mansour L, Masri A, Kayserili H, Al-Aama JY, Abdel-Salam GMH, Karminejad A, Kara M, Kara B, Bozorgmehri B, Ben-Omran T, Mojahedi F, El Din Mahmoud IG, Bouslam N, Bouhouche A, Benomar A, Hanein S, Raymond L, Forlani S, Mascaro M, Selim L, Shehata N, Al-Allawi N, Bindu PS, Azam M, Gunel M, Caglayan A, Bilguvar K, Tolun A, Issa MY, Schroth J, Spencer EG, Rosti RO, Akizu N, Vaux KK, Johansen A, Koh AA, Megahed H, Durr A, Brice A, Stevanin G, Gabriel SB, Ideker T, Gleeson JG. Novarino G, et al. Among authors: issa my. Science. 2014 Jan 31;343(6170):506-511. doi: 10.1126/science.1247363. Science. 2014. PMID: 24482476 Free PMC article.
Phenotypic continuum of NFU1-related disorders.
Kaiyrzhanov R, Zaki MS, Lau T, Sen S, Azizimalamiri R, Zamani M, Sayin GY, Hilander T, Efthymiou S, Chelban V, Brown R, Thompson K, Scarano MI, Ganesh J, Koneev K, Gülaçar IM, Person R, Sadykova D, Maidyrov Y, Seifi T, Zadagali A, Bernard G, Allis K, Elloumi HZ, Lindy A, Taghiabadi E, Verma S, Logan R, Kirmse B, Bai R, Khalaf SM, Abdel-Hamid MS, Sedaghat A, Shariati G, Issa M, Zeighami J, Elbendary HM, Brown G, Taylor RW, Galehdari H, Gleeson JJ, Carroll CJ, Cowan JA, Moreno-De-Luca A, Houlden H, Maroofian R. Kaiyrzhanov R, et al. Among authors: issa m. Ann Clin Transl Neurol. 2022 Dec;9(12):2025-2035. doi: 10.1002/acn3.51679. Epub 2022 Oct 18. Ann Clin Transl Neurol. 2022. PMID: 36256512 Free PMC article.
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, Issa M, Haladyj E, De La Torre I, Grond S, Wollenberg A. Taylor PC, et al. Among authors: issa m. Adv Ther. 2023 Apr;40(4):1867-1883. doi: 10.1007/s12325-023-02445-w. Epub 2023 Feb 20. Adv Ther. 2023. PMID: 36802049 Free PMC article. Clinical Trial.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP. Bieber T, et al. Among authors: issa m. J Dermatolog Treat. 2023 Dec;34(1):2161812. doi: 10.1080/09546634.2022.2161812. J Dermatolog Treat. 2023. PMID: 36546346 Free article.
Editorial Commentary.
Wendel EC, Carney KJ, Issa MM. Wendel EC, et al. Among authors: issa mm. Urol Pract. 2018 Jul;5(4):304. doi: 10.1016/j.urpr.2017.07.006. Epub 2018 Apr 27. Urol Pract. 2018. PMID: 37312312 No abstract available.
Glioblastoma stem cell metabolism and immunity.
Hawly J, Murcar MG, Schcolnik-Cabrera A, Issa ME. Hawly J, et al. Among authors: issa me. Cancer Metastasis Rev. 2024 Mar 26. doi: 10.1007/s10555-024-10183-w. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 38530545 Review.
A Brainstem Mass Lesion.
Castillo Almeida NE, Trejo-Lopez JA, Issa M, Sampathkumar P. Castillo Almeida NE, et al. Among authors: issa m. Clin Infect Dis. 2022 Aug 25;75(2):356-357. doi: 10.1093/cid/ciab786. Clin Infect Dis. 2022. PMID: 36007258 No abstract available.
668 results